CytoDyn Inc (CYDY)

1.50 0.00  0.00% OTC Markets Oct 22, 16:00 USD
View Full Chart
Price Chart
View All CYDY News

News

View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: CytoDyn Inc is a US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes on exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
  • URL: https://www.cytodyn.com
  • Investor Relations URL: N/A
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: N/A
  • Last Earnings Release: N/A
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.